Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis
Patients with diffuse large B-cell lymphoma (DLBCL) who also had pre-existing depression, anxiety, or both had a worse prognosis than those without these pre-existing mental health conditions, according to results from a population-based study. Among over 13,000 patients at a median follow-up of 2 years, the 5-year overall survival (OS) rate was 27% for patients […]
Transapical Transcatheter Mitral Valve Replacement Trial Raises Questions
PHOENIX — Global experience with the novel Intrepid transapical transcatheter mitral valve replacement (TMVR) device through 2 years showed high risks of mortality and complications, raising concerns that might not be alleviated by the planned shift to a transfemoral approach. In the analysis pooling data from a pilot study and the APOLLO trial, the high-risk […]
Americans With Heart Disease Less Likely to Use Wearable Devices
Fewer Americans with or at risk for cardiovascular disease (CVD) used a wearable health monitoring device than the general population, according to a nationally representative sample using 2019-2020 Health Information National Trends Survey (HINTS) data. Only 18% of adults with CVD and 26% of those at risk for CVD reported using a wearable device to […]
Diet tracking: How much is enough to lose weight? ‘You don’t need to have perfect tracking every day to lose a clinically significant amount of weight’
Keeping track of everything you eat and drink in a day is a tedious task that is tough to keep up with over time. Unfortunately, dutiful tracking is a vital component for successful weight loss, however, a new study in Obesity finds that perfect tracking is not needed to achieve significant weight loss. Researchers from […]
How To Protect Kids When The Air Quality Is Terrible
In these warm early days of summer, parks are generally filled with kids playing through the long daylight hours. But right now, in a dark echo of the pandemic, schoolyards and playgrounds throughout the Northeastern U.S. sit empty. N-95 masks are again in high demand as air quality remains “unhealthy” and even “hazardous” with the […]
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer
CHICAGO — Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived significantly longer if they received the selective FGFR inhibitor erdafitinib (Balversa) instead of chemotherapy, a randomized trial showed. Median overall survival (OS) increased from 7.8 months with physician’s choice of chemotherapy to 12.1 months with the targeted agent. Progression-free survival (PFS) […]
Insomnia Symptoms Tied to Stroke a Decade Later
Insomnia symptoms were associated with an increased risk for stroke, according to a population-cohort study using data from the Health and Retirement Study (HRS). People reporting less severe insomnia (HR 1.16, 95% CI 1.02-1.33) and more severe insomnia (HR 1.51, 95% CI 1.29-1.77) saw an increased risk of stroke over an average 9 years of […]
Breathing Support Type Matters for Preventing Extubation Failure in the PICU
Postextubation use of certain modes of noninvasive respiratory support was associated with fewer incidents of extubation failure in critically ill children, a meta-analysis found. Compared with conventional oxygen therapy, both continuous positive airway pressure (CPAP; OR 0.43, 95% credible interval [CrI] 0.17-1.0) and high-flow nasal cannula (HFNC; OR 0.64, 95% CrI 0.24-1.0) appeared more effective […]
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
CHICAGO — Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in the second line for early relapsed or refractory large B-cell lymphoma had significantly longer overall survival (OS) than those treated with standard care, according to an analysis of the ZUMA-7 trial. At a median follow-up of 47.2 months […]
Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
CHICAGO — An “adaptive response” treatment strategy identified a subset of patients with HER2-positive early breast cancer who benefited from a chemotherapy-free treatment plan, according to the phase II PHERGain trial. The strategy is based on evaluating an early response to a dual HER2 blockade with trastuzumab (Herceptin) and pertuzumab (Perjeta) with 18F-FDG PET imaging […]